TDThemistocles Dassopoulos

Themistocles Dassopoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Themistocles Dassopoulos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Principles of Medical Management of Ulcerative Colitis

    by Hongha T. Vu, Themistocles Dassopoulos

  • Positioning Therapy for Crohn’s Disease

    by Alexandra Gutierrez, Themistocles Dassopoulos

    The therapy of Crohn’s disease is constantly evolving. It is widely recognized that clinical assessment does not stage disease activity accurately and that endoscopic healing is associated with improved long-term outcomes. Disease management is therefore transitioning to a new paradigm that includes direct assessment of disease severity (endoscopically in most patients), followed by assessment of mucosal healing. New approaches have helped optimize the use of the thiopurines, methotrexate and anti-TNF agents. Novel agents with different mechanisms of action are expanding our therapeutic armamentarium. The major challenge of the future will be to identify patient subgroups best suited to particular therapeutic approaches. In the meantime, studies of comparative effectiveness will be crucial in positioning therapies relative to each other.

  • Open Access

    Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease

    by T. Dassopoulos, M. C. Dubinsky, J. L. Bentsen, C. F. Martin, J. A. Galanko, E. G. Seidman, R. S. Sandler, S. B. Hanauer

    Summary: Background: Azathioprine (AZA), a pro‐drug metabolised to the active metabolites 6‐tioguanine nucleotides (6TGN), is a steroid‐sparing therapy for Crohn's disease (CD).Aim: To investigate whether AZA therapy is optimised by individualised dosing based on thiopurine methyltransferase (TPMT) activity and 6TGN concentrations.Methods: This multicentre, double‐blind, randomised controlled trial compared the efficacy and safety of weight‐based vs. individualised AZA dosing in inducing and maintaining remission in adults and children with steroid‐treated CD. The primary outcome was clinical remission (CR) at 16 weeks. In the weight‐based arm, subjects received 2.5 mg/kg/day. In the individualised dosing arm, the initial AZA dose was 1.0 mg/kg/day (if intermediate TPMT) or 2.5 mg/kg/day (if normal TPMT). Starting at week 5, the dose was adjusted to target 6TGN concentrations of 250–400 pmol/8 × 108 red blood cells (RBC), or to a maximal dose of 4 mg/kg/day.Results: After randomising 50 subjects, the trial was stopped prematurely due to insufficient enrolment. In intention‐to‐treat analysis, CR rates at week 16 were 40% in the individualised arm vs. 16% in the weight‐based arm (P = 0.11). In per‐protocol (PP) analysis, week 16 CR rates were 60% in the individualised arm and 25% in the weight‐based arm (P = 0.12). At week 16, median 6TGN concentrations in PP remitters and nonremitters were 216 and 149 pmol/8 × 108 RBC respectively (P = 0.07).Conclusions: Despite trends favouring individualised over weight‐based AZA dosing, there were no statistically significant differences in efficacy, likely due to low statistical power and inability to achieve the target 6TGN concentrations in the individualised arm. [Clinicaltrials.Gov Identifier Nct00113503].


  • Thiopurine therapy in inflammatory bowel disease

    by Christina Ha, Themistocles Dassopoulos

    The thiopurines azathioprine and 6-mercaptopurine have been used in the treatment of Crohn's disease and ulcerative colitis for over 40 years. Randomized controlled trials have supported their use in the treatment of active disease, as well as for the maintenance of disease remission. Presently, the most debated issues surrounding the thiopurines include: the role of thiopurine methyltransferase and metabolite-adjusted dosing in enhancing efficacy and minimizing toxicity; the timing of thiopurine use, that is, earlier versus later use during the course of the disease; the selection of thiopurine monotherapy versus combination therapy with an anti-TNF-alpha agent; and the safety profile of thiopurines. Accumulated evidence has supported the safety of 6-mercaptopurine/azathioprine use in pregnancy and lactation. Thiopurine therapy in inflammatory bowel diseases is associated with an increased risk of lymphoproliferative disorders. Factoring their proven efficacy over a broad range of clinical scenarios within Crohn's disease and ulcerative colitis together with their overall safety profile and convenient and inexpensive once-daily oral administration, azathioprine and 6-mercaptopurine remain among the mainstays of Crohn's disease and ulcerative colitis therapy.